nicorandil (chemical compound)

DBpedia resource is: http://dbpedia.org/resource/Nicorandil

Abstract is: Nicorandil is a vasodilatory drug used to treat angina. Angina is chest pain that results from episodes of transient myocardial ischemia. This can be caused by diseases such as atherosclerosis, coronary artery disease and aortic stenosis. Angina commonly arises from vasospasm of the coronary arteries. There are multiple mechanisms causing the increased smooth muscle contraction involved in coronary vasospasm, including increased Rho-kinase activity. Increased levels of Rho-kinase inhibit myosin phosphatase activity, leading to increased calcium sensitivity and hypercontraction. Rho-kinase also decreases nitric oxide synthase activity, which reduces nitric oxide concentrations. Lower levels of nitric oxide are present in spastic coronary arteries. L-type calcium channel expression increases in spastic vascular smooth muscle cells, which could result in excessive calcium influx, and hypercontraction. It was patented in 1976 and approved for medical use in 1983.

External links are

P267	ATC code	C01DX16
P233	canonical SMILES	C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]
P231	CAS Registry Number	65141-46-0
P683	ChEBI ID	31905
P592	ChEMBL ID	CHEMBL284906
P661	ChemSpider ID	43240
P715	DrugBank ID	DB09220
P11198	DrugCentral ID	1919
P8494	DSSTOX compound identifier	DTXCID6025692
P3117	DSSTox substance ID	DTXSID8045692
P232	EC number	265-514-1
P2566	ECHA Substance Infocard ID	100.059.541
P646	Freebase ID	/m/0cpmck
P595	Guide to Pharmacology Ligand ID	2411
P2057	Human Metabolome Database ID	HMDB0255584
P234	InChI	InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
P235	InChIKey	LBHIOVVIQHSOQN-UHFFFAOYSA-N
P665	KEGG ID	C13280
		D01810
P486	MeSH descriptor ID	D020108
P672	MeSH tree code	D02.583.575
		D03.066.515.530.498
		D03.383.725.547.530.498
P6366	Microsoft Academic ID	2778902376
P10283	OpenAlex ID	C2778902376
P11199	Probes And Drugs ID	PD000223
P662	PubChem CID	47528
P3345	RxNorm ID	31748
P4964	SPLASH	splash10-000i-0900000000-9439cd529fafd85e86db
P2877	SureChEMBL ID	SCHEMBL34547
P4527	UK Parliament thesaurus ID	453289
P11089	UniChem compound ID	52190
P652	UNII	260456HAM0

Reverse relations

research intervention (P4844)

Q64653980	A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization
Q63402073	China-Administration of Nicorandil Group（CHANGE）
Q105493065	Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention
Q63337441	Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement
Q87931722	Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts
Q64375516	Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction
Q113918708	Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction
Q61921569	Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
Q64601844	Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Q64376226	Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction
Q67133575	Efficacy Study of Nicorandil on Neointima
Q66075798	Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Subjects
Q66067811	Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
Q63011405	Hyperemic Efficacy of IV Adenosine in HFrEF
Q65545512	Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP
Q102154811	Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC
Q106637877	Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH
Q66401339	Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients
Q64680486	Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients
Q102154661	Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention
Q61935804	Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study)
Q63572777	Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil
Q62030858	Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development
Q64660608	Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Q74275271	Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Q63807577	Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.

main subject (P921)

Q38120580	Conjunctival and corneal ulceration associated with nicorandil
Q42255527	Corneal perforation: another side effect of nicorandil
Q87931722	Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts
Q38260630	Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis
Q64080872	Effect of sequential nicorandil on myocardial microcirculation and short-term prognosis in acute myocardial infarction patients undergoing coronary intervention
Q64235374	Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: A meta-analysis of randomized controlled trials
Q102154811	Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC
Q64081042	Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials
Q88127842	Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt-sensitive hypertensive rats
Q38212442	Preparative isolation and high-resolution mass identification of 10 stressed study degradants of nicorandil tablets
Q58822325	Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers

P4250	defined daily dose	40
P527	has part(s)	carbon	Q623
		oxygen	Q629
P366	has use	medication	Q12140
P2067	mass	211.059306
P129	physically interacts with	Potassium inwardly rectifying channel subfamily J member 11	Q6414726
		Potassium inwardly-rectifying channel, subfamily J, member 8	Q21497890
P3489	pregnancy category	Australian pregnancy category B3	Q3679234
P769	significant drug interaction	aspirin	Q18216
P2868	subject has role	vitamin B	Q183206
		antiarrhythmic agent	Q241549
		antihypertensive drug	Q575890
		vasodilator agent	Q4008956
P2275	World Health Organisation international non-proprietary name	nicorandil

Q6414726	Potassium inwardly rectifying channel subfamily J member 11
Q21497890	Potassium inwardly-rectifying channel, subfamily J, member 8

Q72804745	Effects of a new antianginal agent, nicorandil, on normoxic and anoxic contractions in isolated miniature pig coronary arteries exposed to 5-hydroxytryptamine and norepinephrine: Comparison with nitroglycerin and diltiazem	cites work	P2860
Q18216	aspirin	significant drug interaction	P769

	Category:Nicorandil	wikimedia
Arabic (ar / Q13955)	نيكورانديل	wikipedia
	Nicorandil	wikipedia
Persian (fa / Q9168)	نیکوراندیل	wikipedia
	Nicorandil	wikipedia
	Nicorandil	wikipedia
	ニコランジル	wikipedia
	Nikorandil	wikipedia
	Nicorandil	wikipedia
	Никорандил	wikipedia
Serbo-Croatian (sh / Q9301)	Nikorandil	wikipedia
	Nikorandil	wikipedia
	Нікорандил	wikipedia

nicorandil

chemical compound

Reverse relations

The articles in Wikimedia projects and languages